Purpose: To evaluate the correlation of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), aspartate aminotransferase-to-lymphocyte ratio (ALRI), systemic inflammation index (SII), and lymphocyte count to oncologic outcomes in metastatic colorectal cancer (mCRC) patients undergoing transarterial radioembolization (TARE). Materials and Methods: All patients undergoing TARE for mCRC were retrospectively reviewed at a single academic institution. A receiver operating characteristics (ROC) curve analysis was performed using a landmark survival point of 12 months, with an area under the curve (AUC) calculated. A cutoff point was determined by Youden’s index and used to separate patients for OS and PFS analysis. Cox proportional-hazards models which included pertinent clinical factors were also created to evaluate PFS and OS. Results: In total, 41 patients who underwent 66 TARE treatments were included. A correlation was seen between post-treatment ALRI < 45 (HR: 0.38 (95%CI: 0.17–0.86), p = 0.02) and PFS. Patients with a pretreatment ALRI score < 20 had a significantly longer OS (HR: 0.49 (95%CI: 0.19–0.88), p = 0.02) as did those with a post-treatment lymphocyte count > 1.1 109/L (HR: 0.27 (95%CI: 0.11–0.68), p = 0.005). In multivariate analysis of PFS, post-treatment lymphocyte count (HR: 8.46 (95%CI: 1.14–62.89), p = 0.044) was the only significantly associated inflammatory marker and presence of extrahepatic disease (HR:8.46 (95%CI: 1.14–62.89, p = 0.044) also correlated. Multivariate analysis of OS showed that pretreatment PLR (HR:1.01 (95%CI:1.−1.03), p = 0.02) and post-treatment NLR (HR:0.33 (95%CI:0.14–0.76), p = 0.009), PLR (HR:0.98 (95%CI:0.97–1), p = 0.046), SII (HR:1.04 (95%CI:1.01–1.08), p = 0.014), and lymphocyte count (HR:0.07 (95%CI:0.01–0.16), p = 0.003) were significantly associated. Conclusion: Inflammatory markers may be associated with OS and PFS in mCRC patients undergoing TARE.
|Original language||English (US)|
|Number of pages||11|
|Journal||Cardiovascular and Interventional Radiology|
|State||Published - Feb 2023|
Bibliographical noteFunding Information:
This study was not supported by any funding.
© 2022, Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
- Colorectal cancer
- Inflammatory markers
- Transarterial radioembolization
PubMed: MeSH publication types
- Journal Article